CN114599978A - 使用c-met抑制剂治疗癌症患者的方法 - Google Patents

使用c-met抑制剂治疗癌症患者的方法 Download PDF

Info

Publication number
CN114599978A
CN114599978A CN202080055590.1A CN202080055590A CN114599978A CN 114599978 A CN114599978 A CN 114599978A CN 202080055590 A CN202080055590 A CN 202080055590A CN 114599978 A CN114599978 A CN 114599978A
Authority
CN
China
Prior art keywords
met
leu
ser
val
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055590.1A
Other languages
English (en)
Chinese (zh)
Inventor
杨岚
施前
S·瑞德卡
余国良
F·M·贝内代蒂
X·张
B·马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Guanke Meibo Biotechnology Co ltd
Original Assignee
Zhejiang Guanke Meibo Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Guanke Meibo Biotechnology Co ltd filed Critical Zhejiang Guanke Meibo Biotechnology Co ltd
Publication of CN114599978A publication Critical patent/CN114599978A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202080055590.1A 2019-06-06 2020-06-08 使用c-met抑制剂治疗癌症患者的方法 Pending CN114599978A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019090294 2019-06-06
CNPCT/CN2019/090294 2019-06-06
CN2019092706 2019-06-25
CNPCT/CN2019/092706 2019-06-25
CN2019109906 2019-10-08
CNPCT/CN2019/109906 2019-10-08
PCT/CN2020/094824 WO2020244654A1 (en) 2019-06-06 2020-06-08 Method for treating cancer patients using c-met inhibitor

Publications (1)

Publication Number Publication Date
CN114599978A true CN114599978A (zh) 2022-06-07

Family

ID=73653139

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055590.1A Pending CN114599978A (zh) 2019-06-06 2020-06-08 使用c-met抑制剂治疗癌症患者的方法

Country Status (6)

Country Link
US (1) US20220252603A1 (https=)
EP (1) EP3980783A4 (https=)
JP (1) JP2022535880A (https=)
CN (1) CN114599978A (https=)
CA (1) CA3142642A1 (https=)
WO (1) WO2020244654A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112592976B (zh) * 2020-12-30 2021-09-21 深圳市海普洛斯生物科技有限公司 一种检测met基因扩增的方法及装置
MX2023012434A (es) * 2021-04-21 2024-02-08 Apollomics Inc Diagnostico y tratamiento de cancer usando inhibidor de c-met.
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221825A (zh) * 2010-08-31 2013-07-24 基因泰克公司 生物标志物和治疗方法
WO2014032498A1 (en) * 2012-09-03 2014-03-06 Crown Bioscience Inc. (Taicang) Highly selective c-met inhibitors as anticancer agents
CN106008339A (zh) * 2016-06-08 2016-10-12 武汉绿海棕生物科技有限公司 一种放射性c-met靶向亲和小分子化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113013A2 (en) * 2007-03-15 2008-09-18 University Of Chicago C-met mutations and uses thereof
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221825A (zh) * 2010-08-31 2013-07-24 基因泰克公司 生物标志物和治疗方法
WO2014032498A1 (en) * 2012-09-03 2014-03-06 Crown Bioscience Inc. (Taicang) Highly selective c-met inhibitors as anticancer agents
CN106008339A (zh) * 2016-06-08 2016-10-12 武汉绿海棕生物科技有限公司 一种放射性c-met靶向亲和小分子化合物及其应用

Also Published As

Publication number Publication date
CA3142642A1 (en) 2020-12-10
WO2020244654A1 (en) 2020-12-10
EP3980783A4 (en) 2023-09-13
EP3980783A1 (en) 2022-04-13
US20220252603A1 (en) 2022-08-11
JP2022535880A (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
CN114599978A (zh) 使用c-met抑制剂治疗癌症患者的方法
US20240218453A1 (en) Diagnostic and treatment of cancer using c-met inhibitor
CA2597673C (en) Methods and compositions for detecting a drug resistant egfr mutant
Dhakras et al. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma
CN102006886A (zh) 抗-tweak受体抗体的治疗用途
KR20120106935A (ko) 암의 치료를 위한 진단 방법 및 조성물
AU2014357354A1 (en) Identification of predictive biomarkers associated with Wnt pathway inhibitors
KR20190087106A (ko) 위암의 항암제 치료 반응성 예측용 바이오마커 및 이의 용도
CA2983890A1 (en) Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
JP2008533991A (ja) 肺癌におけるｃ−ｍｅｔ突然変異
US20220145403A1 (en) Method of classifying a sample based on determination of fgfr
JP6858563B2 (ja) Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測
US10815533B2 (en) Biomarker for diagnosing anticancer drug resistance of gastric cancer and use thereof
KR20200092382A (ko) 유전자 발현 검정을 이용한 펩티드 수용체 방사선요법의 예측
JP6312660B2 (ja) Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
AU2020311564B2 (en) Determining individual HLA patterns, use as prognosticators, target genes and therapeutic agents
CN113498341A (zh) 使用多靶点激酶抑制剂结合蛋白激酶生物标志物的癌症治疗
HK40130056A (zh) 使用c-met抑制剂治疗对egfr tki具有耐药性的癌症
Hoorens et al. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists
CN120359030A (zh) 使用c-MET抑制剂治疗对EGFR TKI具有耐药性的癌症
Porth Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
US20240247065A1 (en) Methods of treatment of cancer patients having altered setd2 biomarker with a pd-1 antagonist
CN121285387A (zh) 利用her3抗原结合分子治疗和预防癌症
HK40061707A (en) Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
EP3088521A1 (en) Method for detecting lung cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220607